Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
Maximilian Marhold(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), A. Halstead(University of Bristol), Kerstin Wimmer(Comprehensive Cancer Center Vienna), Kathrin Strasser‐Weippl(Otto Wagner Hospital), Tim Robinson(University of Bristol), Muna Ferner, Ruth Exner(Comprehensive Cancer Center Vienna), Simon Udovica, Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Mona Hirdler(Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas), Florian Fitzal
Cited by 30
Related Papers
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis
|Nature Communications|2020|694
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422